Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > Treated Patients 13 to 30
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(638)
•••
Comment by floatinketuckyon Mar 10, 2022 1:18pm
83 Views
Post# 34503643

RE:RE:Treated Patients 13 to 30

RE:RE:Treated Patients 13 to 30Best to consider all.
floatinketucky wrote: Can you include in this line up the original 8 of 12 who recieved or will  the 2nd dose at full strength?

How many 8 of 12 have gotten the full dose now... cause in the begining some were undertreated by like over 150 percent and some just 30 percent under treatment or a about 70 percent dose...     
99942Apophis wrote: fully optimized patients 

Patients 13 & 14 announced Dec 7/2020 1 year Dec/2021 450 days March 7/2022

Patient 15 announced  Feb 24/2021 1 year Feb 24/2022  450 days May 24/2022

Patient  16 announced March 25/2021 270 day Dec 25/2021 1 year March 25/2022

Patient 17 & 18  announced April 27/2021 270 day Feb 27/2022 1 year April 27/2022

Patient 19  announced May 28/2021  270 day Feb 28/2022 1 year May 28/2022

Patient 20 announced June 11/2021 270 day March 11/2022 1 year June 11/2022

Patient 21 to 24 announced Aug 30/2021 180 day March 2/2022

Patient 25 to 30 announced Nov 29/2021 90 day March 1/2022

 




<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities